Table 2.
Sensitivity and specificity of CSF biomarkers or ratios based on a systematic review of the literature. In each Of these studies either amyloid PET or autopsy was the basis for detection of AD pathology.
| Sensitivity | Specificity | AUROC* | N | |
|---|---|---|---|---|
| 4 consecutive memory clinic studies; amyloid PET | ||||
| Aβ1-42 | 87.6 | 85.2 | 0.90 | 748 participants |
| Aβ1-42/Aβ1-40 | 96.0 | 91.3 | 0.96 | 315 participants |
| 13 case control, multicenter & cohort studies; amyloid PET | ||||
| Aβ1-42 | 93.2 | 84.5 | 0.93 | 2,346 participants |
| Aβ1-42/Aβ1-40 | 96.0 | 88.0 | 0.94 | 200 participants |
| 5 case control or cohort studies; autopsy diagnosis of AD | ||||
| Aβ1-42 | 90.0 | 84.0 | 0.92 | 764 participants |
| Aβ1-42/t-tau | 88.7 | 88.3 | 0.93 | |
| Aβ1-42/p-tau181 | 92.3 | 82.3 | 0.91 |
*
Area Under the Receiver Operating Characteristic curve; data from reference #9 Appendices.